Work

Abstract LB455: Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-lb455

Authors: Fritiof Åkerström, Xavier Catena, Marta Santiago, Ana Perego, Ruixian Liu, Arun Sundaramurthy, Lihan Xie, Emilie Renaud, Andreea-Medeea Matei, Xiaoli Huang, Emma Leire, Ozcan Met, Inge-Marie Svane, Shane Olwill, Cristiana Pires, Filipe Pereira, Fabio Rosa

Institutions: Copenhagen University Hospital, Lund University

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154684215

Cites:

Cited by:

Related to: